Insider Selling: Edge Therapeutics Inc (EDGE) Insider Sells $50,550.00 in Stock
Edge Therapeutics Inc (NASDAQ:EDGE) insider Brian A. Leuthner sold 5,000 shares of the business’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $10.11, for a total transaction of $50,550.00. Following the completion of the sale, the insider now directly owns 87,736 shares in the company, valued at approximately $887,010.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Edge Therapeutics Inc (NASDAQ:EDGE) opened at $10.40 on Friday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 8.34 and a current ratio of 8.34. Edge Therapeutics Inc has a one year low of $7.30 and a one year high of $13.13.
Edge Therapeutics (NASDAQ:EDGE) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.11. sell-side analysts expect that Edge Therapeutics Inc will post -1.7 EPS for the current year.
Several institutional investors have recently modified their holdings of EDGE. Janus Henderson Group PLC bought a new stake in shares of Edge Therapeutics in the second quarter worth $21,962,000. JPMorgan Chase & Co. grew its stake in shares of Edge Therapeutics by 223.4% in the third quarter. JPMorgan Chase & Co. now owns 379,075 shares of the biotechnology company’s stock worth $4,063,000 after purchasing an additional 261,850 shares during the last quarter. Sphera Funds Management LTD. grew its stake in shares of Edge Therapeutics by 122.5% in the third quarter. Sphera Funds Management LTD. now owns 333,737 shares of the biotechnology company’s stock worth $3,581,000 after purchasing an additional 183,737 shares during the last quarter. State Street Corp grew its stake in shares of Edge Therapeutics by 16.3% in the second quarter. State Street Corp now owns 277,352 shares of the biotechnology company’s stock worth $2,847,000 after purchasing an additional 38,909 shares during the last quarter. Finally, Goldman Sachs Group Inc. acquired a new position in Edge Therapeutics in the second quarter valued at $374,000. 50.26% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was first posted by Marea Informative and is owned by of Marea Informative. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.mareainformativa.com/2018/01/06/insider-selling-edge-therapeutics-inc-edge-insider-sells-50550-00-in-stock.html.
About Edge Therapeutics
Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.
Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.